source
- Stealthy biotech Treeline Biosciences to go public via reverse merger with Standard BioToolsTreeline Biosciences announced a plan to become a public company through a reverse merger with microfluidics firm Standard BioTools. The transaction will give Standard shareholders about 15.5% of…
- Lilly proposes up to $1 billion for Alzheimer’s candidate, while Bial drops Parkinson’s programOn June 9, 2026, Eli Lilly announced a potential licensing agreement for an Alzheimer’s disease candidate, offering an upfront payment of $10 million and the possibility of more than $1 billion bas…